Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 1;110(3):1699-1710.
doi: 10.1097/JS9.0000000000001022.

Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis

Lei Zhang  1 , Han Zheng, Shi-Tao Jiang, Yao-Ge Liu, Ting Zhang, Jun-Wei Zhang, Xin Lu, Hai-Tao Zhao, Xin-Ting Sang, Yi-Yao Xu
Affiliations
Review

Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis

Lei Zhang et al. Int J Surg. .

Abstract

Various immunotherapy has been greatly applied to comprehensive treatment of malignant cancer under different degrees of tumor burden. Scientific researchers have gained considerable progress in the relationship between immunotherapy and tumor burden in recent years. This review aimed to explore the prospect and developing trends in the field of tumor burden and immunotherapy from a bibliometric perspective. Articles about tumor burden and immunotherapy were collected from the Web of Science Core Collection (WoSCC) (retrieved on 3 January 2023). The R package 'Bibliometrix' analyzed the primary bibliometric features and created a three-filed plot to display the relationship between institutions, countries, and keywords. VOSviewer was used for co-authorship analysis, co-occurrence analysis, and their visualization. And CiteSpace calculated the citation burst references and keywords. A total of 1030 publications were retrieved from 35 years of scientific researches. The United States (US) and China published the most articles. The most productive journals were Cancer Immunology Immunotherapy and Journal for ImmunoTherapy of Cancer . The top one institution of the highest output was University of Texas MD Anderson Cancer Center. The hot keywords of strong citation burst strength in recent years were 'nivolumab', 'tumor microenvironment', and 'immune checkpoint inhibitor'. The most popular tumor type is melanoma. This bibliometric analysis mapped a basic knowledge structure. The field of tumor burden and immunotherapy is entering a rapid growing stage and keeping it value for future research.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Figures

Figure 1
Figure 1
Workflow of the study.
Figure 2
Figure 2
The annual number and the cumulative number of publications.
Figure 3
Figure 3
A map of country contribution based on the article output.
Figure 4
Figure 4
The top 11 institutions with the most publications.
Figure 5
Figure 5
The top 20 most used keywords.
Figure 6
Figure 6
Three-field plot of the keywords plus analysis on tumor burden and immunotherapy (Left field: institutions; Middle field: keywords; Right field: countries).
Figure 7
Figure 7
Keyword co-occurrence network.
Figure 8
Figure 8
Keyword co-occurrence plus time-overlapping network.
Figure 9
Figure 9
The top 25 keywords with robust citation bursts.
See this image and copyright information in PMC

References

    1. Hodi FS, O’Day SJ, McDermott DF, et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723. - PMC - PubMed
    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350–1355. - PMC - PubMed
    1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432–1433. - PubMed
    1. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 2016;16:566–581. - PMC - PubMed
    1. Grupp SA, Kalos M, Barrett D, et al. . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–1518. - PMC - PubMed